R&D expense · 2011–2025
Biomarin Pharmaceutical R&D expense
$922M+23.4% · FY2025
Biomarin Pharmaceutical (BMRN) reported $922M in R&D expense for fiscal 2025, +23.4% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $922M | +23.4% | Open → |
| FY20242024-12-31 | $747M | +0.1% | Open → |
| FY20232023-12-31 | $747M | +15.0% | Open → |
| FY20222022-12-31 | $650M | +3.3% | Open → |
| FY20212021-12-31 | $629M | +0.1% | Open → |
| FY20202020-12-31 | $628M | −12.2% | Open → |
| FY20192019-12-31 | $715M | +2.7% | Open → |
| FY20182018-12-31 | $696M | +14.0% | Open → |
| FY20172017-12-31 | $611M | −7.7% | Open → |
| FY20162016-12-31 | $662M | +4.3% | Open → |
| FY20152015-12-31 | $635M | +37.5% | Open → |
| FY20142014-12-31 | $462M | +30.1% | Open → |
| FY20132013-12-31 | $355M | +17.4% | Open → |
| FY20122012-12-31 | $302M | +41.0% | Open → |
| FY20112011-12-31 | $214M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +11.0%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Biomarin Pharmaceutical R&D expense |url=https://companiesranked.com/en/company/biomarin-pharmaceutical/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Biomarin Pharmaceutical R&D expense. CompaniesRanked. https://companiesranked.com/en/company/biomarin-pharmaceutical/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-biomarin-pharmaceutical-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Biomarin Pharmaceutical R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/biomarin-pharmaceutical/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001048477-26-000004 · February 26, 2026
{{cite web |title=Biomarin Pharmaceutical R&D expense — 10-K (0001048477-26-000004) |url=https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/bmrn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.